Rachel S. Kerr

Old Road Campus Research Building, Roosevelt Drive
Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 81 publications

Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.

Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 09, 2026

The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.

The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.

Journal: JAMA oncology

Published: October 02, 2025

Iatrogenic Subcapsular Haematoma Leads to 151% Growth of Future Liver Remnant.

Iatrogenic Subcapsular Haematoma Leads to 151% Growth of Future Liver Remnant.

Journal: Cardiovascular and interventional radiology

Published: February 25, 2025

Analysis of IDH1 and IDH2 mutations as causes of the hypermethylator phenotype in colorectal cancer.

Analysis of IDH1 and IDH2 mutations as causes of the hypermethylator phenotype in colorectal cancer.

Journal: The Journal of pathology

Published: December 19, 2024

Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis.

Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis.

Journal: ESMO open

Published: November 27, 2024

Activin A affects colorectal cancer progression and immunomodulation in a stage dependent manner.

Activin A affects colorectal cancer progression and immunomodulation in a stage dependent manner.

Journal: Scientific reports

Published: September 10, 2024

Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis.

Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 04, 2024

Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical Trial.

Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical Trial.

Journal: JAMA surgery

Published: June 12, 2024

Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.

Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 28, 2024

Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.

Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 14, 2024

Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes.

Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes.

Journal: Nature communications

Published: October 16, 2023

Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials.

Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 27, 2023

Showing 1-12 of 81

Last Updated: 09/26/2026